The following was the study question for this meta-analysis: “What proportion of patients experience change in their management when 68Ga-PSMA PET is used versus conventional imaging modalities (CT, MRI)?” Utilizing 68Ga-PSMA-PET for the initial staging of prostate cancer may result in the modification of initial treatment plans in a significant number of patients. The gene discussed is FOLH1; the disease is prostate carcinoma.